WHO Expert Committee on Drug Dependence Pre-Review

..........................

Delta-9-tetrahydrocannabinol

Section 5: Epidemiology

This report contains the views of an international group of experts, and does not necessarily represent the decisions or the stated policy of the World Health Organization
This is an advance copy distributed to the participants of the 40th Expert Committee on Drug Dependence, before it has been formally published by the World Health Organization. The document may not be reviewed, abstracted, quoted, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means without the permission of the World Health Organization.

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

The World Health Organization does not warrant that the information contained in this publication is complete and correct and shall not be liable for any damages incurred as a result of its use.
Acknowledgments

This report was prepared by the Secretariat of the Expert Committee on Drug Dependence (ECDD) within the Department of Essential Medicines and Health Products (EMP) of the World Health Organization (WHO), Geneva, Switzerland. The WHO staff involved in the production of this document, developed under the overall guidance of Mariângela Simão (Assistant Director General, Access to Medicines, Vaccines, and Pharmaceuticals), Suzanne Hill (Director, Essential Medicines and Health Products), Gilles Forte, (Secretary of the Expert Committee on Drug Dependence) were Dilkushi Poovendran (Technical Officer, WHO Essential Medicines and Health Products) and Wil De Zwart (Technical Officer, WHO Essential Medicines and Health Products).

This report was commissioned as a background document for a preliminary review for the 40th Expert Committee on Drug Dependence (ECDD). WHO would like to acknowledge the contributions of the following individuals who authored this report:

Chemistry
Giuseppe Cannazza (University of Modena and Reggio Emilia), Italy
Cinzia Citti (University of Modena and Reggio Emilia), Italy

Pharmacology
Jenny Wiley (RTI International), USA

Epidemiology
Haya Fernandez (Centre for Addiction and Mental Health), Canada
Vidhi Thakkar (Centre for Addiction and Mental Health), Canada
Omer S.M. Hasan (Centre for Addiction and Mental Health), Canada
Jakob Manthey (Institute for Clinical Psychology and Psychotherapy), Germany
Jurgen Rehm (Centre for Addiction and Mental Health), Canada
Astrid Otto (Centre for Addiction and Mental Health), Canada
Charlotte Probst (Centre for Addiction and Mental Health), Canada
Julian Sauer (Centre for Addiction and Mental Health), Canada

Toxicology
Jonathon Arnold (University of Sydney), Australia

Therapeutic Use
Kevin P. Hill (Harvard Medical School), USA
Judith Spahr, (Thomas Jefferson University) USA
Charles V. Pollack, (Thomas Jefferson University) USA
Brock Bakewell (Thomas Jefferson University), USA

The Member State questionnaire report was prepared by Jurgen Rehm, Astrid Otto, and Jakob Manthey. Technical editing was provided by Ann Morgan and Susan Kaplan. Administrative support was provided by Afrah Vogel and Christine Berling.
Contents

1. Industrial use ........................................................................................................................................... 5
2. Non-medical use, abuse and dependence ................................................................................................. 6
3. Nature and magnitude of public health problems related to misuse, abuse and dependence 7
4. Licit production, consumption, international trade ..................................................................................... 8
5. Illicit manufacture and traffic ..................................................................................................................... 9
6. References .................................................................................................................................................. 10
1. **Industrial use**

In our rapid systematic review of the peer-reviewed literature, there were no studies that focused on the industrial use of pure THC other than for therapeutic use (see Appendices 1 and 2, in particular Figure A2). At this point, at least based on a systematic review of the peer-reviewed literature, industrial use seems to be limited to therapeutic use.

In the following, we will only report on applications of pure THC (e.g. dronabinol; (4)); the therapeutic use of THC in combination with other substances (e.g., cannabidiol (5, 6) is described in Report 2 (7)).

To give some examples of therapeutic use from the systematic search: as an analgesic, 10 mg of THC has been found comparable to 60 mg of codeine, and doses of 3.5–10 mg/day of synthetic THC have been found to be effective in multiple sclerosis patients (8). Two trials investigating the use of pure THC for pain associated with multiple sclerosis (9) or fibromyalgia (10) found some evidence of symptom relief, suggesting doses higher than 10 mg/day; however, one study found significant pain reductions to be limited to immediately after THC administration (9) and the other study noted that 5 of 9 patients withdrew due to the adverse event of sedation (10). Three studies on appetite stimulation in patients with cancer or HIV, using doses of THC ranging from 5-7.5 mg/day or 0.1-0.2mg/kg, found some improvement (11) while one trial found no difference in appetite for cancer patients taking either pure THC, THC and cannabidiol, or placebo (12). A survey on therapeutic cannabis use in a study in Germany reported average THC doses of 14.9 mg/day (range: 4-35 mg/day; N=14); symptoms being treated included neurological, gastrointestinal and pain (13).

In regard to the clinical use of pure THC, liquid dronabinol is typically marketed in a 5 mg/mL form (14) or in capsules of 2.5, 5 or 10 mg (15). One trial in cancer patients with cachexia found bi-daily dosing of 2.5 mg dronabinol to be more effective for both increasing appetite and decreasing weight loss as compared to either 2.5 mg/day or 5 mg/day (14). A review on the use of THC for cancer-related cachexia indicated that individual titration may be more effective than fixed dosing (16) and this has been suggested for HIV wasting syndrome as well (15). Doses of 5 mg and 10 mg dronabinol were associated with increased caloric intake in regular marijuana users with HIV; however, tolerance to dronabinol is a concern when treating marijuana users (14).
2. **Non-medical use, abuse and dependence**

Tinctures and extracts of cannabis for medical reasons date to Chinese applications documented 4000-5000 years ago (8, 17). In Europe and North America, use was introduced in the 19th century. Pure THC preparations are more recent and dronabinol (synthetic pure THC) was approved in 1985 in the US.

While pure THC has potential for non-medical use and abuse, such non-medical use seems to be rare (4, 18). A small trial reported no results to date ([https://clinicaltrials.gov/ct2/show/NCT02094599](https://clinicaltrials.gov/ct2/show/NCT02094599)).
3. **Nature and magnitude of public health problems related to misuse, abuse and dependence**

No reports were found of public health problems of pure THC.
4. **Licit production, consumption, international trade**

The results of our systematic review did not yield any articles related to licit production, consumptions, or international trade of pure THC.
5.  Illicit manufacture and traffic

No indication of illicit manufacture or traffic was found in the peer-reviewed literature.
6. References


Appendix 1: Original Search Strategy for peer-reviewed articles on Delta-9-tetrahydrocannabinol

The following systematic searches of the peer-reviewed literature were conducted originally based on the PRISMA guidelines (19, 20) and using three databases via OVID on March 8, 2018:

1. Embase
2. Medline
3. PsycINFO

The search was restricted to literature published in 2000 and onwards. Various search strategies were explored by the authors independently using different combinations of keywords and MeSH terms pertinent to epidemiology, cannabis-related compounds, substance abuse, self-medication and therapeutic use. This was done to determine an optimal unanimous search strategy for each report, to identify the most relevant studies, respecting the short timeframe available to prepare this Pre-Review.

As a result, Report 3 (on Delta-9-tetrahydrocannabinol) and 4 (Isomers of THC) shared the same search parameters due to a low search count for isomers of THC, which was a subset of the results obtained from the searches for Report 3. Results from the searches were screened in parallel by different authors of this report (HF, VT, OSMH, JR), and any studies relevant to a parallel report were exchanged between the authors during the review.

Table A1: Original search strategy for Report 3

<table>
<thead>
<tr>
<th>No.</th>
<th>Searches</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Human/ or humans/</td>
<td>36244807</td>
</tr>
<tr>
<td>2</td>
<td>limit 1 to yr=&quot;2000 -Current&quot;</td>
<td>21066974</td>
</tr>
<tr>
<td>3</td>
<td>(bibliography or case reports or clinical conference or conference abstract or conference paper or conference proceeding or &quot;conference review&quot; or comment or editorial or in vitro or letter).pt.</td>
<td>8530671</td>
</tr>
<tr>
<td>4</td>
<td>2 not 3</td>
<td>16300231</td>
</tr>
<tr>
<td>5</td>
<td>epidemiology or exp epidemiology/</td>
<td>3693795</td>
</tr>
<tr>
<td>6</td>
<td>prevalence or exp prevalence/</td>
<td>1580556</td>
</tr>
<tr>
<td>7</td>
<td>incidence or exp incidence/</td>
<td>1888341</td>
</tr>
<tr>
<td>8</td>
<td>population or exp population/</td>
<td>3537733</td>
</tr>
<tr>
<td>9</td>
<td>5 or 6 or 7 or 8</td>
<td>8094152</td>
</tr>
<tr>
<td>10</td>
<td>delta-9-tetrahydrocannabinol</td>
<td>6047</td>
</tr>
</tbody>
</table>
A full list of references can be found in a separate Reference Appendix document.

Reviewing the studies for inclusion was a two-step screening process:

1. Based on title and abstract screening, studies with minimal uncertainty were excluded.
2. Based on full-text review of studies remaining at step 1, studies were selected for final inclusion and data was abstracted at this point.

Each step of the review was led by a pilot screening of 20 studies to maintain consistency between the authors taking part in the review. In addition, coding of studies was compared systematically for 20 studies between VT, HF, OSMH and JR. The authors also met on a weekly basis throughout the duration of the review to discuss the progress of the reports and to resolve any conflicts during study selection and coding. The results of the searches are summarized in Figure 3.

Figure A1: PRISMA Diagram for Report 3 (21)
Of 1055 studies retrieved from the search, 179 were included after screening of title and abstract (see Appendix 1 for Reports 3 for details). After full-text screening, 95 studies were included in report 1. Review articles were excluded from analysis but were kept for the background of the report and inserted into the various chapters.

However, no articles were found on pure THC. This has led to a revised search strategy (see Appendix 2).
Appendix 2: Revised search Strategy for peer-reviewed articles on Delta-9-tetrahydrocannabinol

Please find below the revised strategy for searches on pure THC. The searches were carried out in the same databases on Monday April 30, 2018, after exploring several other options the days before.

Table A2: Revised search strategy for Report 3

<table>
<thead>
<tr>
<th>Searches</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>1  Human/ or humans/</td>
<td>36624572</td>
</tr>
<tr>
<td>2  limit 1 to yr=&quot;2000-Current&quot;</td>
<td>21436269</td>
</tr>
<tr>
<td>3  (bibliography or case reports or clinical conference or conference abstract or conference paper or conference proceeding or &quot;conference review&quot; or comment or editorial or in vitro or letter or clinical trial).pt.</td>
<td>8678776</td>
</tr>
<tr>
<td>4  2 not 3</td>
<td>16557485</td>
</tr>
<tr>
<td>5  *Dronabinol/</td>
<td>7689</td>
</tr>
<tr>
<td>6  pure thc</td>
<td>33</td>
</tr>
<tr>
<td>7  pure delta-9-tetrahydrocannabinol</td>
<td>6</td>
</tr>
<tr>
<td>8  5 or 6 or 7</td>
<td>7708</td>
</tr>
<tr>
<td>9  epidemiology.mp. or exp epidemiology/</td>
<td>3754882</td>
</tr>
<tr>
<td>10 prevalence.mp. or exp prevalence/</td>
<td>1606016</td>
</tr>
<tr>
<td>11 population.mp. or exp population/</td>
<td>3590357</td>
</tr>
<tr>
<td>12 9 or 10 or 11</td>
<td>7186552</td>
</tr>
<tr>
<td>13 4 and 8 and 12</td>
<td>114</td>
</tr>
<tr>
<td>14 remove duplicates from 13</td>
<td>103</td>
</tr>
</tbody>
</table>

Note on terminology and search strategy

With regard to chapter headings, we used the headings as specified in the WHO Request for Proposals. In the text, we did not use terms like misuse or abuse, which are not or not consistently defined within the current medical classification systems (1, 2), and thus we only use the terms cannabis use, cannabis use disorders and cannabis dependence. All terms are defined in the text, based on the above cited current medical classification systems.

The literature searches were not restricted to the above-mentioned medical terminology. They were restricted to pure Delta-9-tetrahydrocannabinol (THC). If articles were reporting THC in general (e.g. as indication of cannabis use in a region by measuring THC in wastewater), the findings were included in Report 1 (3).
All full-text articles assessed for eligibility can be found on a separate Appendix file.
**Appendix 3: Abbreviations**

- **BCO:** Butane Cannabis Oil
- **CI:** 95% Confidence interval
- **DSM-IV:** Diagnostic and Statistical Manual of Mental Disorders – 4th Edition
- **DSM-5:** Diagnostic and Statistical Manual of Mental Disorders – 5th Edition
- **DUI:** Driving Under the Influence
- **EMCDDA:** European Monitoring Centre for Drugs and Drug Addiction
- **ESPAD:** European School Survey Project on Alcohol and Other Drugs
- **EU:** European Union
- **GBD:** Global Burden of Disease
- **ICD-10:** International Classification of Diseases – 10th Revision
- **INCB:** International Narcotics Control Board
- **IUPAC:** International Union of Pure and Applied Chemistry
- **MC:** Medical cannabis (abbreviated only in the respective chapter)
- **UNODC:** United Nations Office on Drugs and Crime
- **THC:** Tetrahydrocannabinol (Δ9-tetrahydrocannabinol)
- **WDR:** World Drug Report
- **WHO:** World Health Organization